Table 2.

ORs and 95% CIs for the association between metabolic syndrome and endometrial cancer, SEER–Medicare

Noncases (N = 100,751)All cases (N = 16,323)Additionally adjusted for overweight/obesityMutually adjusted model
n (%)n (%)ORa (95% CI)ORb (95% CI)ORc (95% CI)
Metabolic conditions
 Overweight/obesity3,390 (3.4)1,107 (6.8)1.95 (1.80–2.11)1.77 (1.63–1.92)
 Impaired fasting glucose20,568 (20.4)4,320 (26.5)1.36 (1.30–1.43)1.38 (1.31–1.44)1.25 (1.19–1.31)
 High blood pressure63,703 (63.2)11,129 (68.2)1.31 (1.25–1.36)1.28 (1.23–1.33)1.21 (1.15–1.26)
 Low HDL cholesterol279 (0.3)58 (0.4)
 High triglycerides30,354 (30.1)6,155 (37.7)1.13 (1.08–1.18)1.11 (1.07–1.16)1.03 (0.99–1.08)
Metabolic syndromed
 NCEP-III9,930 (9.9)2,505 (15.3)1.39 (1.32–1.47)1.21 (1.14–1.29)
 IDF2,105 (2.1)753 (4.6)2.03 (1.84–2.23)1.17 (0.99–1.38)
  • aORs adjusted for diagnosis date, age, race/ethnicity, registry area, and tobacco use.

  • bORs adjusted for diagnosis date, age, race/ethnicity, registry area, tobacco use, and overweight/obesity.

  • cORs adjusted for diagnosis date, age, race/ethnicity, registry area, tobacco use, overweight/obesity, impaired fasting glucose, high blood pressure, and high triglycerides.

  • dNCEP-III: US National Cholesterol Education Program Adult Treatment Panel III defines metabolic syndrome as the presence of at least three of the following conditions: central adiposity/elevated waist circumference, hypertension, high triglycerides, low HDL cholesterol, and impaired fasting glucose; IDF: International Diabetes Foundation defines metabolic syndrome as the presence of central adiposity/elevated waist circumference plus any 2 of the other factors (impaired fasting glucose, hypertension, low HDL cholesterol, and high triglycerides).